The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.
Morningstar's Daniel Rohr and asset management CEO Kevin Carter battle it out over the future and...
We like much of what we see at BGF Pacific Equity, but it’s too soon to have a high degree of con...
Arnout van Rijn has this fund on the right track, but a couple of issues concern us.
Asian markets have moved up slightly so far this year while world markets have remained virtually...
The question facing investors in Asia is whether the region can repeat last year’s strong perform...
Mining companies are operating in a challenging environment but could now be the time to top up o...
THE WEEK: Morningstar columnist Rodney Hobson provides two pieces of advice to George Osborne, an...
Businesses that have competitive advantages within their industry are good candidates for dividen...
Morningstar reveals the top 10 best performers over the last five years
Morningstar OBSR reveals the top funds for investors seeking exposure to European equities
The bank also announced a deal with Metro Bank, raised its guidance, and increased its dividends
With revenue growth, increased operating margins, but a high valuation, here’s what we think of N...
We'll be watching iPhone revenue, gross margins, and services growth when Apple reports its earni...
Despite growth, Morningstar's Fair Value Estimate for the consumer goods giant stock is unchanged
Morningstar analysts think the UK's biggest company has a well-positioned broad drug portfolio wh...